Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 5/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.42 |
| ▸ | CCR5 | P51681 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241198 | 0.90 | UBE2M (0.47) | UBE2MDCUN1D1CCR5CNR1CNR2 | |
| SCHEMBL4242936 | 0.87 | CCR5 (0.40) | UBE2MDCUN1D1CCR5 | |
| SCHEMBL4248482 | 0.83 | CCR5 (0.41) | UBE2MDCUN1D1CCR5 | |
| SCHEMBL4242202 | 0.82 | CCR5 (0.51) | CCR5TAS2R14 | |
| SCHEMBL4241358 | 0.82 | CCR5 (0.41) | UBE2MDCUN1D1CCR5 | |
| SCHEMBL4247034 | 0.81 | CCR5 (0.57) | CCR5 | |
| SCHEMBL4236874 | 0.81 | CCR5 (0.47) | CCR5 | |
| SCHEMBL4242432 | 0.81 | CCR5 (0.48) | UBE2MDCUN1D1CCR5 | |
| SCHEMBL4238954 | 0.81 | CCR5 (0.48) | CCR5 | |
| SCHEMBL4236938 | 0.80 | UBE2M (0.42) | UBE2MDCUN1D1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | UBE2M 4562/4885DCUN1D1 3581/4885CXCR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.